Barclays raised the firm’s price target on Elevance Health (ELV) to $395 from $373 and keeps an Overweight rating on the shares as part of a Q3 earnings preview for the health care facilities and managed care group. The firm continues to think Medicare is the most stable, Medicaid the most uncertain, and the Affordable Care Act exchanges are inflecting positively from both a fundamental and policy perspective.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health price target raised to $398 from $360 at Guggenheim
- Elevance Health price target raised to $412 from $330 at Wells Fargo
- Sector Spotlight: UnitedHealth shareholder proposes split of CEO, chair role
- Trump Trade: White House announces drug pricing deal with Pfizer
- Health Insurance subsidies central to government shutdown negotiation, WSJ says